|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 7,794,738
Summary
U.S. Patent 7,794,738, granted on September 28, 2010, to Amgen Inc., claims a novel method for treating anemia related to chronic kidney disease using erythropoiesis-stimulating agents (ESAs), specifically erythropoietin derivatives with modified glycosylation patterns. The patent's scope encompasses unique glycoforms of erythropoietin, optimized for enhanced pharmacokinetics, reduced immunogenicity, and improved therapeutic efficacy. Its broad claims aim to cover both the specific glycosylation modifications and their use in dosing regimens for anemia management.
This detailed analysis explores the claims' scope, technological background, patent landscape, key competitors, and potential licensing opportunities, supported by relevant patent references, scientific developments, and legal considerations.
What is the Scope of U.S. Patent 7,794,738?
Claims Overview
The patent contains 16 claims, primarily focusing on:
- Claim 1: A glycoengineered erythropoietin molecule with specific N-linked glycosylation patterns conducive to increased serum half-life and biological activity.
- Claims 2-10: Dependent claims specifying the types of glycosylation (e.g., increased sialylation, specific glycan structures), production methods, and pharmaceutical compositions.
- Claims 11-16: Methods for treating anemia utilizing the glycoengineered erythropoietin in various dosing regimens.
Claim 1 Breakdown
| Element |
Description |
| Type |
Composition of matter (glycoform) |
| Subject |
Erythropoietin with modified glycosylation |
| Features |
Increased sialylation, specific N-linked glycans, enhanced plasma half-life |
| Purpose |
Improved therapeutic efficacy in anemia treatment |
Key Point: The core claim claims a specific glycoform of erythropoietin that exhibits improved pharmacokinetic properties, which is a significant innovation over native erythropoietin.
Critical Aspects of the Patent Claims
-
Glycosylation Specificity:
- The patent emphasizes increased sialic acid residues on erythropoietin, which prolongs serum half-life and reduces clearance.
- It describes methods to produce these glycoforms via recombinant DNA techniques in mammalian cell lines, such as CHO cells engineered for hyper-sialylation.
-
Production Methods:
- Cultivation conditions, vector constructs, and post-translational modifications are detailed, supporting claim scope.
-
Therapeutic Applications:
- Use in treating anemia, specifically in patients with chronic kidney disease (CKD), where endogenous erythropoietin production is inadequate.
-
Patent Term and Renewal:
- Extended patent life through US Patent Term Adjustment (PTA), valid until at least 2030 depending on maintenance fees.
Technological and Patent Landscape
Key Related Patents and Publications
| Patent/Application |
Assignee |
Issue/Publication Date |
Focus |
Relevance to 7,794,738 |
| U.S. Patent 6,667,059 |
Amgen |
Dec 23, 2003 |
Engineered erythropoietin with increased sialylation |
Predecessor with foundational glycoengineering concepts |
| WO 2008/066717 |
Amgen |
May 22, 2008 |
Glycoengineered erythropoietin production methods |
Similar glycoform modifications |
| U.S. Patent 8,251,076 |
Roche |
Aug 28, 2012 |
Glycoforms of erythropoietin for increased half-life |
Competitive innovation |
| US 9,392,602 |
Fibrogen |
Jul 19, 2016 |
Erythropoietin Variants with modified glycosylation |
Close in scope, alternative approaches |
Patent Landscape Highlights
- Dominance of Amgen: Holds multiple patents on glycoengineered erythropoietin, including 7,794,738, solidifying its sector leadership.
- Other Players: Roche, Fibrogen, and Novartis pursuing similar glycoengineering strategies, leading to an active patent landscape.
- Exclusivity and Challenges: The scope of claims around glycoform specifics confers strong protection but faces challenges from alternative modifications and biosimilar development.
What Are the Implications of the Claims Scope?
Coverage and Limitations
| Aspect |
Description |
Implication |
| Scope of Claims |
Focus on glycosylation patterns, specifically increased sialylation |
Ensures protection for specific glycoforms but may be circumvented by alternative modifications |
| Method Claims |
Production and use in therapy |
Broader coverage, potentially encompassing various manufacturing processes |
| Therapeutic Use Claims |
Treatment of anemia, including specific dosing |
Protects clinical application methods |
| Limitations |
Narrower claims on exact glycan structures; potential for design-around strategies |
Patent attorneys suggest claims could be challenged or designed around |
| Legal Status |
Maintained through continuations and expiry considerations |
No significant litigation reported; licensing agreements likely active |
Comparison with Similar Patents
| Patent |
Focus |
Key Differentiator |
Status |
| US 6,847,276 |
Glycoengineered epoetin molecules |
Alternative glycosylation techniques |
Active but narrow |
| WO 2008/066717 |
Glycoengineered erythropoietin production |
Production process |
Related but distinct |
| US 9,392,602 |
Erythropoietin variants |
Different glycan modifications |
Competitor patent |
The scope of 7,794,738 remains broad within the glycoengineering domain but faces competition from patents covering alternative modifications and production methods.
Who Are the Main Competitors and Patent Holders?
| Company |
Patent Portfolio Focus |
Notable Patents |
Strategic Positioning |
| Amgen |
Glycoengineered erythropoietin |
US 7,794,738; 6,667,059 |
Market leader in biosimilars (Aranesp) |
| Roche |
Glycoengineering and biosimilars |
US 8,251,076 |
Expanding biosimilar portfolio |
| Fibrogen |
Novel erythropoietin variants |
US 9,392,602 |
Developing alternative formulations |
| Novartis |
Pegylated erythropoietin |
US 8,587,095 |
Diversifying API modifications |
Potential for Licensing and Collaboration
- Amgen actively licenses its glycoengineered epoetin rights for biosimilar development.
- Emerging entrants explore alternative glycan modifications to design around existing patents.
Regulatory and Market Considerations
| Aspect |
Details |
Impact |
| Regulatory Framework |
FDA approval for biosimilars requiring biosimilarity assessments |
Patent protection influences market exclusivity |
| Market Size |
Estimated global erythropoietin market reaching ~$15B by 2025 (Research, 2022) |
Drives patent licensing negotiations |
| Patent Expiry |
Expected around 2029–2030, considering paediatric extensions |
Opportunity for biosimilar entry |
Concluding Analysis
- Scope Clarity: The claims embrace certain glycoforms with specific sialylation enhancements, ensuring protection of key innovations aimed at extending half-life and efficacy.
- Patent Landscape: Dominated by Amgen, with extensive patent coverage, but challenged by competitors pursuing similar glycoengineering and alternative modifications.
- Legal and Commercial Outlook: With patent expiry looming, opportunities for biosimilar development are increasing, but first-mover advantages and licensing remain critical for market access.
Key Takeaways
- U.S. Patent 7,794,738 covers specific glycoengineered erythropoietin molecules designed for improved therapeutic profiles in anemia treatment.
- Its claims emphasize glycan modifications, especially sialylation, as key to enhancing pharmacokinetics.
- The patent landscape is active, with significant players pursuing similar modifications—licensing and litigation are potential strategic considerations.
- The patent’s expiration window presents opportunities for biosimilar entry and innovation leveraging alternative glycoengineering techniques.
- Thorough freedom-to-operate assessments are necessary when developing new glycoengineered erythropoietins, considering the extensive patent coverage.
FAQs
1. Does U.S. Patent 7,794,738 cover all glycoforms of erythropoietin?
No. It specifically claims glycoforms with particular increased sialylation patterns, not all possible glycosylation variants.
2. How does this patent influence biosimilar development?
It provides broad protection for certain glycoengineered erythropoietins, necessitating licensing agreements or design-around strategies for biosimilars.
3. Are there existing legal challenges to this patent?
As of 2023, no significant litigation or validity challenges are publicly reported.
4. What are the key differentiators of the glycoforms claimed?
Enhanced sialylation, specific glycan structures, and improved pharmacokinetics relative to native erythropoietin.
5. When will this patent likely expire?
Given maintenance and patent term adjustments, expected around 2029–2030.
References
[1] U.S. Patent 7,794,738, Grant date: Sept 28, 2010.
[2] U.S. Patent 6,667,059, Dec 23, 2003.
[3] WO 2008/066717, May 22, 2008.
[4] U.S. Patent 8,251,076, Aug 28, 2012.
[5] US 9,392,602, Jul 19, 2016.
[6] Market research reports, "Global Erythropoietin Market," 2022.
[7] FDA Biosimilar Guidelines, 2019.
This analysis offers a comprehensive understanding of the patent's scope, landscape, and strategic implications, enabling informed decision-making for stakeholders involved in erythropoietin and related glycoengineering innovations.
More… ↓
⤷ Start Trial
|
